Reneo Pharmaceuticals to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)
Reneo Pharmaceuticals (Nasdaq: RPHM) announced that data from its Phase 1 leg immobilization study of REN001 will be presented at the 17th International Congress on Neuromuscular Diseases in Brussels (July 5-9, 2022). The study showed REN001 was safe and well tolerated, effectively preventing muscle atrophy and enhancing muscle recovery compared to placebo. REN001, a PPARδ agonist, is aimed at treating rare genetic mitochondrial diseases, with ongoing trials including the STRIDE study for primary mitochondrial myopathies.
- REN001 demonstrated safety and tolerability in the Phase 1 study.
- The drug prevented muscle atrophy and improved recovery of muscle strength compared to placebo.
- Renowned presentation at an international congress enhances visibility.
- No detailed financial metrics were disclosed in the PR.
- Regulatory and market uncertainties remain concerning upcoming clinical trial results.
IRVINE, Calif., June 30, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that data from the Company’s Phase 1 leg immobilization study of REN001 in healthy volunteers has been accepted for presentation at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022) being held in Brussels, Belgium July 5-9, 2022.
In the study, REN001 was safe and well tolerated. Compared to placebo, REN001 prevented muscle atrophy, promoted faster recovery of muscle strength, and increased transcription of genes involved in mitochondrial biogenesis and function.
Presentation:
Treatment with REN001, a Novel PPARδ Agonist, Compared to Placebo, Preserves Muscle Strength and Promotes Recovery of Muscle Atrophy After Prolonged Leg Immobilization in Healthy Male Adults
Date & Time:
Friday, July 8, 2022 at 5:00 pm CEST (8:00 am PT)
About Reneo Pharmaceuticals
Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, REN001, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.
About REN001
REN001 is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in clinical development for two rare genetic mitochondrial diseases that typically present with myopathy and have high unmet medical needs: primary mitochondrial myopathies (PMM) (STRIDE Study) and long-chain fatty acid oxidation disorders (LC-FAOD). For more information on REN001 clinical trials, please see clinicaltrials.gov.
About PMM
PMM are a group of disorders caused by genetic mutations within the mitochondrial DNA or nuclear DNA that affect the activity of enzymes or other proteins in the mitochondria. In PMM these genetic alterations hamper the ability of mitochondria to generate energy from nutrient sources, resulting in energy deficits that are most pronounced in tissues with high energy demand such as muscle, brain, and heart. The symptoms of PMM include muscle weakness or exercise intolerance, movement disorder, deafness, blindness, and droopy eyelids among others. The prognosis for these disorders ranges in severity from progressive weakness to death.
About STRIDE
STRIDE is a global, randomized, double-blind, placebo-controlled Phase 2b clinical trial designed to assess the efficacy and safety of 100 mg REN001 administered orally once daily to patients with PMM. Approximately 200 adult PMM patients with alterations in mitochondrial DNA and a history of myopathy are expected to be enrolled into STRIDE. The primary efficacy endpoint of the trial is the change from baseline in the distance walked during a 12-minute walk test (12MWT) after 24 weeks of treatment. Secondary efficacy endpoints include safety, and patient reported outcomes including changes from baseline in the Modified Fatigue Impact Scale (MFIS), Patient Global Impression of Change scale (PGIC), and other patient-reported outcomes.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the results, conduct, progress and timing of Reneo’s clinical trials, presentation of data from clinical trials, the regulatory approval path for REN001 intellectual property protection matters, the strength of Reneo’s balance sheet and the adequacy of cash on hand. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans,” “will,” “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Reneo’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Reneo’s business in general, and the other risks described in Reneo’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Reneo undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Contacts:
Joyce Allaire
Managing Director
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Gregory J. Flesher
Chief Executive Officer
Reneo Pharmaceuticals, Inc.
investors@reneopharma.com
FAQ
What were the results of the Phase 1 study for REN001 by Reneo Pharmaceuticals?
When will the data from the REN001 study be presented?
What is REN001 and its purpose?
What is the STRIDE study related to Reneo Pharmaceuticals?
What is the stock symbol for Reneo Pharmaceuticals?
